These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 31654285)

  • 1. Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma.
    Wood A; George S; Adra N; Chintala S; Damayanti N; Pili R
    Invest New Drugs; 2020 Aug; 38(4):1108-1116. PubMed ID: 31654285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators.
    Beider K; Bitner H; Voevoda-Dimenshtein V; Rosenberg E; Sirovsky Y; Magen H; Canaani J; Ostrovsky O; Shilo N; Shimoni A; Abraham M; Weiss L; Milyavsky M; Peled A; Nagler A
    Biochem Pharmacol; 2019 Oct; 168():412-428. PubMed ID: 31325448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
    Bitting RL; Healy P; Creel PA; Turnbull J; Morris K; Wood SY; Hurwitz HI; Starr MD; Nixon AB; Armstrong AJ; George DJ
    Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.
    Zibelman M; Wong YN; Devarajan K; Malizzia L; Corrigan A; Olszanski AJ; Denlinger CS; Roethke SK; Tetzlaff CH; Plimack ER
    Invest New Drugs; 2015 Oct; 33(5):1040-7. PubMed ID: 26091915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer.
    Deutsch E; Le Péchoux C; Faivre L; Rivera S; Tao Y; Pignon JP; Angokai M; Bahleda R; Deandreis D; Angevin E; Hennequin C; Besse B; Levy A; Soria JC
    Ann Oncol; 2015 Jun; 26(6):1223-1229. PubMed ID: 25701455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.
    Oki Y; Buglio D; Fanale M; Fayad L; Copeland A; Romaguera J; Kwak LW; Pro B; de Castro Faria S; Neelapu S; Fowler N; Hagemeister F; Zhang J; Zhou S; Feng L; Younes A
    Clin Cancer Res; 2013 Dec; 19(24):6882-90. PubMed ID: 24097867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma.
    Haas NB; Appleman LJ; Stein M; Redlinger M; Wilks M; Xu X; Onorati A; Kalavacharla A; Kim T; Zhen CJ; Kadri S; Segal JP; Gimotty PA; Davis LE; Amaravadi RK
    Clin Cancer Res; 2019 Apr; 25(7):2080-2087. PubMed ID: 30635337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma.
    Sheng X; Yan X; Chi Z; Cui C; Si L; Tang B; Li S; Mao L; Lian B; Wang X; Bai X; Zhou L; Kong Y; Dai J; Ding L; Mao L; Guo J
    EBioMedicine; 2020 May; 55():102755. PubMed ID: 32335374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors.
    Zhu M; Molina JR; Dy GK; Croghan GA; Qi Y; Glockner J; Hanson LJ; Roos MM; Tan AD; Adjei AA
    Invest New Drugs; 2020 Dec; 38(6):1755-1762. PubMed ID: 32328844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer.
    Ferrari AC; Alumkal JJ; Stein MN; Taplin ME; Babb J; Barnett ES; Gomez-Pinillos A; Liu X; Moore D; DiPaola R; Beer TM
    Clin Cancer Res; 2019 Jan; 25(1):52-63. PubMed ID: 30224345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.
    Hainsworth JD; Spigel DR; Burris HA; Waterhouse D; Clark BL; Whorf R
    J Clin Oncol; 2010 May; 28(13):2131-6. PubMed ID: 20368560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
    Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
    Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.
    Aggarwal R; Thomas S; Pawlowska N; Bartelink I; Grabowsky J; Jahan T; Cripps A; Harb A; Leng J; Reinert A; Mastroserio I; Truong TG; Ryan CJ; Munster PN
    J Clin Oncol; 2017 Apr; 35(11):1231-1239. PubMed ID: 28221861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Islam P; Rizzieri D; Lin C; de Castro C; Diehl L; Li Z; Moore J; Morris T; Beaven A
    Cancer Invest; 2021 Nov; 39(10):871-879. PubMed ID: 34643126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.
    Harzstark AL; Small EJ; Weinberg VK; Sun J; Ryan CJ; Lin AM; Fong L; Brocks DR; Rosenberg JE
    Cancer; 2011 Sep; 117(18):4194-200. PubMed ID: 21387258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma.
    Molina AM; van der Mijn JC; Christos P; Wright J; Thomas C; Dutcher JP; Nanus DM; Tagawa ST; Gudas LJ
    Invest New Drugs; 2020 Oct; 38(5):1383-1389. PubMed ID: 31898184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer.
    Powles T; Foreshew SJ; Shamash J; Sarwar N; Crabb S; Sahdev A; Nixon J; Lim L; Pungaliya A; Foreshaw A; Davies R; Greenwood M; Wilson P; Pacey S; Galazi M; Jones R; Chowdhury S
    Eur J Cancer; 2014 Aug; 50(12):2057-64. PubMed ID: 24908540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression.
    Ellis L; Lehet K; Ramakrishnan S; Adelaiye R; Miles KM; Wang D; Liu S; Atadja P; Carducci MA; Pili R
    PLoS One; 2011; 6(11):e27178. PubMed ID: 22087262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
    Xia C; Leon-Ferre R; Laux D; Deutsch J; Smith BJ; Frees M; Milhem M
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):691-7. PubMed ID: 25062770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTEN Expression, Not Mutation Status in
    Voss MH; Chen D; Reising A; Marker M; Shi J; Xu J; Ostrovnaya I; Seshan VE; Redzematovic A; Chen YB; Patel P; Han X; Hsieh JJ; Hakimi AA; Motzer RJ
    Clin Cancer Res; 2019 Jan; 25(2):506-514. PubMed ID: 30327302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.